Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AADvac1 Phase 1 Follow-up in Alzheimer's Disease
NCT02031198Phase 1Completed
- Sponsor
- Axon Neuroscience
- Start
- Jan 2014
- Primary completion
- Aug 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AADvac1 in Alzheimer's disease (AD), sponsored by Axon Neuroscience. Primary endpoint: Tolerability and safety profile of AADvac1 at 18 months. Started Jan 2014; status: completed.
02
Drugs
AADvac1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02031198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031198.